{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:23:06Z","timestamp":1784067786504,"version":"3.55.0"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"DZIF","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KGaA"},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squibb GmbH"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Liver steatosis is often observed in chronic HCV infection and associated to genotype or comorbidities. NAFLD is an important risk factor for end-stage liver disease. We aimed to analyse the course of NAFLD as a concomitant disease in a cohort of HCV patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The German Hepatitis C-Registry is a national multicenter real-world cohort. In the current analysis, 8789 HCV patients were included and separated based on the presence of steatosis on ultrasound and\/or histology. Fibrosis progression was assessed by transient elastography (TE), ultrasound or non-invasive surrogate scores.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>At the time of study inclusion 12.3% (n = 962) of HCV patients presented with steatosis (+S) (higher rate in GT-3). Diabetes mellitus was more frequent in GT-1 patients. HCV patients without steatosis (-S) had a slightly higher rate of fibrosis progression (FP) over time (30.3%) in contrast to HCV patients +S (26%). This effect was mainly observed in GT-3 patients (34.4% vs. 20.6%). A larger decrease of ALT, AST and GGT from baseline to FU-1 (4\u201324 weeks after EOT) was found in HCV patients (without FP) +S compared to -S. HCV patients -S and with FP presented more often metabolic comorbidities with a significantly higher BMI (+0.58kg\/m<jats:sup>2<\/jats:sup>) compared to patients -S without FP. This was particularly pronounced in patients with abnormal ALT.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Clinically diagnosed steatosis in HCV patients does not seem to contribute to significant FP in this unique cohort. The low prevalence of steatosis could reflect a lower awareness of fatty liver in HCV patients, as patients -S and with FP presented more metabolic risk factors.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0264741","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T20:08:57Z","timestamp":1655410137000},"page":"e0264741","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic impact of steatosis in the clinical course of chronic HCV infection\u2014Results from the German Hepatitis C-Registry"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-4044","authenticated-orcid":true,"given":"Monika","family":"Rau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Mauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H. W.","family":"Boeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"pone.0264741.ref001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40794-016-0038-5","article-title":"Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era","volume":"2","author":"HL Stevenson","year":"2016","journal-title":"Trop Dis Travel Med Vaccines"},{"issue":"4","key":"pone.0264741.ref002","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1055\/s-2004-860869","article-title":"Hepatitis C and nonalcoholic fatty liver disease","volume":"24","author":"S Ramesh","year":"2004","journal-title":"Seminars in liver disease"},{"issue":"26","key":"pone.0264741.ref003","first-page":"447","article-title":"Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment","volume":"111","author":"J Weiss","year":"2014","journal-title":"Deutsches Arzteblatt international"},{"key":"pone.0264741.ref004","article-title":"A new definition for metabolic associated fatty liver disease: an international expert consensus statement","author":"M Eslam","year":"2020","journal-title":"Journal of hepatology"},{"issue":"3","key":"pone.0264741.ref005","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"RJ Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"pone.0264741.ref006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060803","article-title":"NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations","volume":"17","author":"LE Adinolfi","year":"2016","journal-title":"International journal of molecular sciences"},{"issue":"2","key":"pone.0264741.ref007","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2003.11.020","article-title":"Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease","volume":"126","author":"A Lonardo","year":"2004","journal-title":"Gastroenterology"},{"issue":"8","key":"pone.0264741.ref008","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/liv.12781","article-title":"TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism","volume":"35","author":"N Coppola","year":"2015","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"23","key":"pone.0264741.ref009","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.3748\/wjg.v20.i23.7089","article-title":"Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World journal of gastroenterology","volume":"20","author":"A Lonardo","year":"2014","journal-title":"WJG"},{"issue":"6","key":"pone.0264741.ref010","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1053\/j.gastro.2006.03.014","article-title":"Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data","volume":"130","author":"G Leandro","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"pone.0264741.ref011","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2893.2011.01523.x","article-title":"Steatosis and insulin resistance in response to treatment of chronic hepatitis C","volume":"19","author":"F. Negro","year":"2012","journal-title":"J Viral Hepat"},{"issue":"9","key":"pone.0264741.ref012","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2005.04007.x","article-title":"Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C","volume":"20","author":"D Kumar","year":"2005","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"9","key":"pone.0264741.ref013","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/2053","article-title":"The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice","volume":"4","author":"K Moriya","year":"1998","journal-title":"Nat Med"},{"issue":"12","key":"pone.0264741.ref014","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/cncr.22701","article-title":"Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis","volume":"109","author":"JR Pekow","year":"2007","journal-title":"Cancer"},{"issue":"Suppl 2","key":"pone.0264741.ref015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2036.2005.02596.x","article-title":"Review article: non-alcoholic fatty liver disease and hepatitis C\u2014risk factors and clinical implications","volume":"22","author":"AJ Sanyal","year":"2005","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"8","key":"pone.0264741.ref016","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry","volume":"49","author":"T Berg","year":"2019","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"pone.0264741.ref017","article-title":"Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs","author":"F Tacke","year":"2019","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"1","key":"pone.0264741.ref018","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"pone.0264741.ref019","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10620-017-4749-x","article-title":"Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment","volume":"63","author":"J Chan","year":"2018","journal-title":"Digestive diseases and sciences"},{"issue":"41","key":"pone.0264741.ref020","doi-asserted-by":"crossref","first-page":"15233","DOI":"10.3748\/wjg.v20.i41.15233","article-title":"Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World journal of gastroenterology","volume":"20","author":"L Abenavoli","year":"2014","journal-title":"WJG"},{"issue":"8","key":"pone.0264741.ref021","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/17474124.2017.1326816","article-title":"Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients","volume":"11","author":"A Elsharkawy","year":"2017","journal-title":"Expert review of gastroenterology & hepatology"},{"issue":"1","key":"pone.0264741.ref022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12876-019-0973-5","article-title":"Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents","volume":"19","author":"WF Hsu","year":"2019","journal-title":"BMC gastroenterology"},{"issue":"3","key":"pone.0264741.ref023","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"JA Bachofner","year":"2017","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"pone.0264741.ref024","article-title":"Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry","author":"V Knop","year":"2020","journal-title":"J Viral Hepat"},{"issue":"12","key":"pone.0264741.ref025","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy","volume":"23","author":"V Knop","year":"2016","journal-title":"J Viral Hepat"},{"issue":"5","key":"pone.0264741.ref026","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/MEG.0000000000001106","article-title":"Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response","volume":"30","author":"N Kobayashi","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"pone.0264741.ref027","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1038\/s41598-018-26293-9","article-title":"Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter","volume":"8","author":"K Shimizu","year":"2018","journal-title":"Sci Rep."},{"issue":"7","key":"pone.0264741.ref028","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/apt.14554","article-title":"Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy","volume":"47","author":"T Tada","year":"2018","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"1","key":"pone.0264741.ref029","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"M Alexander","year":"2018","journal-title":"BMC medicine"},{"issue":"4","key":"pone.0264741.ref030","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s10620-019-05700-9","article-title":"Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort","volume":"65","author":"A Singh","year":"2020","journal-title":"Digestive diseases and sciences"},{"issue":"11","key":"pone.0264741.ref031","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/apt.15679","article-title":"Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data","volume":"51","author":"R Loomba","year":"2020","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"5","key":"pone.0264741.ref032","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2012.11.021","article-title":"Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal","volume":"58","author":"MV Machado","year":"2013","journal-title":"Journal of hepatology"},{"issue":"5","key":"pone.0264741.ref033","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/apt.15976","article-title":"Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination","volume":"52","author":"E Ogawa","year":"2020","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"11","key":"pone.0264741.ref034","first-page":"1257","article-title":"Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response","volume":"26","author":"N Peleg","year":"2019"},{"issue":"6","key":"pone.0264741.ref035","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease","volume":"155","author":"F Kanwal","year":"2018","journal-title":"Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T20:09:31Z","timestamp":1655410171000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264741"}},"subtitle":[],"editor":[{"given":"Pavel","family":"Strnad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264741","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]}}}